Sanofi snaps up acne vaccine developer Origimm BioSanofi has added to its vaccine pipeline with an agreement to acquire Austria’s Origimm Biotechnology and its vaccine-based Share XSanofi snaps up acne vaccine developer Origimm Biohttps://pharmaphorum.com/news/sanofi-snaps-up-acne-vaccine-developer-origimm-bio/
Chinese tech giant Baidu licenses mRNA algorithm to SanofiSanofi has bolstered its push into mRNA-based therapies with a new licensing deal – but not as might Share XChinese tech giant Baidu licenses mRNA algorithm to Sanofihttps://pharmaphorum.com/news/chinese-tech-giant-baidu-licenses-mrna-algorithm-to-sanofi/
AI specialist Owkin snares $270m alliance with Sanofi in oncologySanofi has made another investment in artificial intelligence, taking a $180 million equity stake in Franco-US startup Owkin Share XAI specialist Owkin snares $270m alliance with Sanofi in oncologyhttps://pharmaphorum.com/news/ai-specialist-owkin-snares-270m-alliance-with-sanofi-in-oncology/
Merck’s oral PCSK9 drug matches injectables in early trialsInjectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Share XMerck’s oral PCSK9 drug matches injectables in early trialshttps://pharmaphorum.com/news/mercks-oral-pcsk9-drug-matches-injectables-in-early-trials/
Sanofi winds $40m into UK gene therapy firm GyroscopeFrench drugmaker Sanofi has made a $40 million investment in Gyroscope Therapeutics, with another $20 million potentially on Share XSanofi winds $40m into UK gene therapy firm Gyroscopehttps://pharmaphorum.com/news/sanofi-winds-40m-into-uk-gene-therapy-firm-gyroscope/
Dupixent scores a first in rare skin disease prurigo nodularisSanofi and Regeneron’s Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising Share XDupixent scores a first in rare skin disease prurigo nodularishttps://pharmaphorum.com/news/dupixent-scores-a-first-in-rare-skin-disease-prurigo-nodularis/
NICE changes stance on Sanofi’s Dupixent for severe asthma18 months after saying “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma Share XNICE changes stance on Sanofi’s Dupixent for severe asthmahttps://pharmaphorum.com/news/nice-changes-stance-on-sanofis-dupixent-for-severe-asthma/
Actemra shortage spills over to include Sanofi’s rival KevzaraRoche’s Actemra has been in high demand since its value in treating severe COVID-19 was established, leading to Share XActemra shortage spills over to include Sanofi’s rival Kevzarahttps://pharmaphorum.com/news/actemra-shortage-spills-over-to-include-sanofis-rival-kevzara/
Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczemaAlready a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category Share XKey drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczemahttps://pharmaphorum.com/news/key-drug-in-sanofis-1-45bn-kymab-buyout-shows-promise-in-eczema/
